19:31 , Mar 1, 2019 |  BC Week In Review  |  Company News

WuXi, ABL expand deal to develop bispecifics

WuXi Biologics Inc. (HKSE:2269) granted ABL Bio Inc. (KOSDAQ:298380) rights to use WuXi's WuXiBody and CD3 platforms to develop and commercialize bispecific antibodies targeting an undisclosed immune checkpoint receptor. The partners said the deal expands...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
18:26 , Jan 11, 2019 |  BC Week In Review  |  Company News

Trigr gets rights to ABL's bispecific antibody

ABL Bio Inc. (KOSDAQ:298380) granted Trigr Therapeutics Inc. (Irvine, Calif.) exclusive rights to TR009 (formerly ABL001, NOV1501), a bispecific antibody targeting δ like canonical Notch ligand 4 (DLL4) and VEGF. Trigr gets worldwide development and...
20:11 , Dec 21, 2018 |  BC Week In Review  |  Financial News

ABL Bio raises $80M in Korean IPO

ABL Bio Inc. (KOSDAQ:298380) raised W90 billion ($80 million) through the sale of 6 million shares at W15,000 in an IPO in South Korea. The offering values the company at W668.8 billion ($594.4 million). In...
18:26 , Nov 7, 2018 |  BioCentury  |  Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
19:30 , Jul 27, 2018 |  BC Extra  |  Company News

I-Mab, ABL partner in antibody deals

I-Mab Biopharma (Shanghai, China) granted ABL Bio Inc. (Seongnam, South Korea) rights to bispecific antibodies against an undisclosed target for $2.5 million up front and up to $97.5 million in milestones, plus royalties. ABL will...
19:32 , Jul 13, 2018 |  BC Week In Review  |  Company News

Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea. ABL will receive $4.3 million up front and be eligible for $550...
23:03 , Jul 2, 2018 |  BC Extra  |  Company News

Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea. ABL will receive $4.3 million up front and be eligible for $550...
20:14 , Jun 15, 2018 |  BC Week In Review  |  Financial News

ABL snags $65M in series C

ABL Bio Inc. (Seongnam, South Korea) raised $65 million on June 8 in a series C round led by new investors DS Asset Management, Alpen Route Asset Management, Quad Asset Management and Hana Financial Investment....
22:43 , Jun 8, 2018 |  BC Extra  |  Financial News

ABL snags $65M in series C

ABL Bio Inc. (Seongnam, South Korea) raised $65 million in a series C round led by new investors DS Asset Management, Alpen Route Asset Management, Quad Asset Management and Hana Financial Investment. ABL has now...